Super Session 8 - Oncology 2025
Thursday, September 10, 2015
•
S18
•
11:30 AM
>
12:30 PM
•
Super Session 8 - Oncology 2025
•
Plenary Room A2
Session hosted by Oslo Cancer Cluster
Oncology is at the forefront of realizing the promises of precision medicine. Huge and complex datasets are exploited for novel drug development as well as for informed and real-time care decisions. Emerging Cancer immunotherapies represent a paradigm shift for cancer treatment triggering a global R&D race and novel partnerships. Furthermore, the convergence of the genetics and digital revolution creates novel types of products, companies and growth opportunities transforming the sector.
In this session, international thought leaders will discuss current game changing innovations and their impact on the industry in the years ahead. Special focus will be on novel partnering and collaboration models to advance innovations towards a changing market.
Moderator: Mr. Richard Godfrey, CEO, BergenBio
Speakers:
Dr. Timothy Fisher, Global Lead, Immuno-Oncology / Oncology, Search & Evaluation, Bristol-Myers Squibb
Dr. Vaios Karanikas, Senior Biomarker and Experimental Medicine Leader, Tumor Immunology, Roche Pharmaceutical Research and Early Development, Translational Medicine Oncology, Roche Innovation Center Zurich
Dr. Anthony Bak, Principal Data Scientist, Ayasdi
Dr. Erik Lund, Director, Worldwide Licensing at MSD (Merck & Co., Inc.)
|